This mechanism also affected the utility of the CX3CR1 score as a predictive biomarker; change of the frequency of CX3CR1+ CD8+ T cells from the baseline did not correlate with response to ICI therapy in patients and tumor-bearing mice on steroids even though steroids were discontinued at the time of steroids initiation. Here, CD8A is linked to neoplasm.